Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city - A retrospective 14-year study

Annals of Hematology

Volumn 88, Issue 7, 2009, Pages 633-637

  Souza, E M ^a   Baiocchi, O C G ^a,c   Zanichelli, M A ^b   Alves, A C ^a   Oliveira, J S R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hospital Estadual Brigadeiro   (Brazil)

^c NONE   (Brazil)

Author keywords

Chemotherapy; Hodgkin's Lymphoma; Overall survival

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CITY; CLINICAL PROTOCOL; COLON ADENOCARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPING COUNTRY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SOUTH AMERICA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BRAZIL; DACARBAZINE; DOXORUBICIN; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HOSPITALS, URBAN; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINBLASTINE; VINCRISTINE; YOUNG ADULT;

EID: 67349083278     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0635-0     Document Type: Article

References (21)

1. Ayres MMA Jr (2005) Bioestatistica - Aplicações estatísticas nas áreas das ciências bio-médicas. Instituto de Desenvolvimento sustentável Mamirauá 45:124-175
2. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975) Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine and imidazole carboxide versus MOPP. Cancer 36:252-259 doi: 10.1002/ 1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7
3. Bonadonna G, Valagussa P, Santoro A (1986) Alternating non-cross resistant combination chemotherapy with ABVD or MOPP in stage IV Hodgkin's disease: A report of eight year results. Ann Intern Med 104:739-746
4. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484
5. Carbone PP, Kaplan HS, Musshoff K (1971) Report of the committee on Hodgkin's disease staging. Cancer Res 31:1860-1861
6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 17:1244-1255
7. DeVita VT Jr, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH et al (1980) Curability of advanced Hodgkin's disease with chemotherapy. Ann Intern Med 92:587-595
8. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B et al (2002) Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20:3484-3494 doi: 10.1200/JCO.2002.09.038
9. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM et al (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614 doi: 10.1200/JCO.2003.12.086
10. Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, Dühmke E, German Hodgkin's Study Group et al (2005) Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's study group. J Clin Oncol 23:5052-5060 doi: 10.1200/ JCO.2005.11.080
11. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R et al (1998) MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The eight year results of the intergroup trial. J Clin Oncol 16:19-26
12. Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-447
13. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506-1514 doi: 10.1056/NEJM199811193392104
14. Hebel JR, Mccarter RJ (2006) Study guide to epidemiology and biostatistics. Jones and Bartlett, Sudbury
15. Hoppe RT (1980) Radiation therapy in the treatment of Hodgkin disease. Semin Oncol 7:144-154
16. Klimo P, Connors JM (1985) MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol 3:1174-1182
17. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES et al (1986) Twenty years of MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 4:1295-1306
18. Ng AK, Bernardo MVP, Weller E, Backstrand K, Silver B, Marcus KC et al (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996 doi: 10.1182/blood-2002-02-0634
19. Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 11:5-22
20. Specht L, Gray RG, Clarke MJ, Peto R (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 Patients. J Clin Oncol 16:830-843
21. Spector N, Costa MA, Pulcheri W, Salgado RC, Nucci M, Andrade CA et al (1993) C-MOPP/ABV yields good results in a public hospital population with Hodgkin disease in Brazil. Cancer 71:2823-2827 doi: 10.1002/ 1097-0142(19930501)71:9<2823::AID-CNCR2820710923>3.0.CO;2-6